What is PRA Health Sciences Price-to-Operating-Cash-Flow?
As of today (2024-05-12), PRA Health Sciences's share price is $165.21.
PRA Health Sciences's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2021 was $8.54. Hence, PRA Health Sciences's Price-to-Operating-Cash-Flow Ratio for today is 19.35.
The historical rank and industry rank for PRA Health Sciences's Price-to-Operating-Cash-Flow or its related term are showing as below:
PRAH'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 13.22 Med: 22.83 Max: 59.85
Current: 19.65
During the past 9 years, PRA Health Sciences's highest Price-to-Operating-Cash-Flow Ratio was 59.85. The lowest was 13.22. And the median was 22.83.
PRA Health Sciences's Cash Flow from Operations per share for the
three
months ended in Mar. 2021 was $2.91.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2021 was $8.54.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of PRA Health Sciences was 86.60% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 24.20% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 18.90% per year.
During the past 9 years, PRA Health Sciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was 94.10% per year. The lowest was 13.70% per year. And the median was 24.80% per year.
PRA Health Sciences Price-to-Operating-Cash-Flow Historical Data
The historical data trend for PRA Health Sciences's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRA Health Sciences Price-to-Operating-Cash-Flow Chart
|
PRA Health Sciences Annual Data
|
|
Trend |
Dec12 |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
21.71 |
26.39 |
17.58 |
28.34 |
18.17 |
|
PRA Health Sciences Quarterly Data
|
|
Jun16 |
Sep16 |
Dec16 |
Mar17 |
Jun17 |
Sep17 |
Dec17 |
Mar18 |
Jun18 |
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
19.77 |
17.46 |
13.54 |
18.17 |
18.26 |
Competitive Comparison of PRA Health Sciences's Price-to-Operating-Cash-Flow
For the Diagnostics & Research subindustry, PRA Health Sciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PRA Health Sciences's Price-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, PRA Health Sciences's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where PRA Health Sciences's Price-to-Operating-Cash-Flow falls into.
PRA Health Sciences Price-to-Operating-Cash-Flow Calculation
PRA Health Sciences's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 165.21 | / | 8.54 |
| = | 19.35 |
PRA Health Sciences's Share Price of today is $165.21.
PRA Health Sciences's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.54.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
PRA Health Sciences (PRA Health Sciences) Business Description
Traded in Other Exchanges
N/A
Address
4130 ParkLake Avenue, Suite 400, Raleigh, NC, USA, 27612
PRA Health Sciences is a global contract research organization that provides drug development and clinical trial services to pharmaceutical and biotechnology firms. Its services run from early- to late-stage clinical trial outsourcing with varying levels of support, including one-off specialized staffing services to strategic partnerships where PRA handles nearly all aspects of the trial. In 2017, PRA acquired Symphony Health, a healthcare data and analytics provider. PRA's competitor, Icon, announced it will acquire PRA for $12 billion, which is scheduled to close in third-quarter 2021.
Executives
| Michael J. Bonello |
officer: EVP & CFO |
4130 PARKLAKE AVENUE, SUITE 400, RALEIGH NY 27612 |
| Shannon Colin |
director, officer: President & CEO |
PRA INTERNATIONAL 12120 SUNSET HILLS ROAD, SUITE 600 RESTON VA 20190 |
| Christopher L Gaenzle |
officer: EVP, CAO & General Counsel |
C/O INC RESEARCH HOLDINGS, INC., 3201 BEECHLEAF COURT, SUITE 600, RALEIGH NC 27604 |
| Glen D. Stettin |
director |
C/O EXPRESS SCRIPTS HOLDING COMPANY, ONE EXPRESS WAY, ST. LOUIS MO 63121 |
| Alexander George Dickinson |
director |
31542 CATALINA AVE LAGUNA BEACH CA 92651 |
| Jeffrey T Barber |
director |
6501 WESTON PARKWAY, SUITE 200 CARY NC 27513 |
| Matthew P. Young |
director |
C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
| Linda S Grais |
director |
86 ALEJANDRA AVE, ATHERTON CA 94027 |
| James C Momtazee |
director |
2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025 |
| George R Roberts |
10 percent owner |
C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 2800 SAND HILL ROAD, MENLO PARK CA 94025 |
| Kkr Pra Investors Gp Ii Llc |
10 percent owner |
9 WEST 57TH STREET, SUITE 4200 NEW YORK NY 10019 |
| Kkr Pra Investors L.p. |
10 percent owner |
9 WEST 57TH STREET, SUITE 4200 NEW YORK NY 10019 |
| Kkr Pra Investors Gp Llc |
10 percent owner |
9 WEST 57TH STREET, SUITE 4200 NEW YORK NY 10019 |
| Kkr North America Xi Ltd |
10 percent owner |
KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019 |
| Kkr North America Fund Xi L.p. |
10 percent owner |
C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 30 HUDSON YARDS, NEW YORK NY 10001 |
PRA Health Sciences (PRA Health Sciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRAH has been successfully added to your